Amgen announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI...
The FDA has approved the supplemental Biologics License Application (sBLA) for Vectibix (panitumumab), from Amgen, for patients with wild-type RAS...
Amgen has announced that a Phase III study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint,...
Amgen has announced results from new retrospective analyses of key studies with Vectibix (panitumumab) in metastatic colorectal cancer (mCRC) patients....
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC): • in first-line in combination with FOLFOX or FOLFIRI. • in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). • as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Amgen has announced detailed results of a Phase III study with Vectibix (panitumumab) and best supportive care (BSC) compared to...
The National Institute for Health and Care Excellence (NICE) has published interim guidance after reviewing both personalised therapies, Vectibix (panitumumab)...
Amgen announced data from the global Phase III CodeBreaK 300 trial evaluating two doses of Lumakras (sotorasib) (960 mg or 240 mg) in combination with Vectibix (panitumumab)